William Rapeport
Plus aucun poste en cours
Profil
William Garth Rapeport was the founder of RespiVert Ltd.
(founded in 2006) and Pulmocide Ltd.
(founded in 2007), where he held the titles of Managing Director and CEO, Director & Chief Medical Officer, respectively.
He also held former positions as Director-Clinical Pharmacology at Glaxo Wellcome Plc, Non-Executive Director at Galapagos NV, Senior Vice President at GSK Plc, and Principal at Pfizer Central Research.
Dr. Rapeport received his undergraduate degrees from the University of Oxford and the University of Glasgow.
Anciens postes connus de William Rapeport
| Sociétés | Poste | Fin |
|---|---|---|
Pulmocide Ltd.
 Pulmocide Ltd. Pharmaceuticals: MajorHealth Technology Pulmocide Ltd. provides biopharmaceutical services. It develops inhaled medicines for viral and fungal infections of the respiratory tract. The company was founded by William Garth Rapeport, John Murray, Kazuhiro Ito, and Peter Strong on March 23, 2007 and is headquartered in London, the United Kingdom. | Directeur Général | 19/12/2019 |
| GALAPAGOS NV | Directeur/Membre du Conseil | 30/06/2010 |
| GSK PLC | Corporate Officer/Principal | - |
| Glaxo Wellcome Plc | Corporate Officer/Principal | - |
| Pfizer Central Research | Corporate Officer/Principal | - |
Formation de William Rapeport
| University of Glasgow | Undergraduate Degree |
| University of Oxford | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| GALAPAGOS NV | Health Technology |
| GSK PLC | Health Technology |
| Entreprise privées | 4 |
|---|---|
RespiVert Ltd.
 RespiVert Ltd. Medical DistributorsDistribution Services RespiVert Ltd. operates as a small molecule drug discovery company. The firm develops small-molecule inhaled therapies for the treatment of chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis. The company was founded by William Garth Rapeport, Peter Strong, Kazuhiro Ito, John Murray and Peter Barnes in 2007 and is headquartered in London, the United Kingdom. | Distribution Services |
| Pfizer Central Research | |
Pulmocide Ltd.
Pulmocide Ltd. Pharmaceuticals: MajorHealth Technology Pulmocide Ltd. provides biopharmaceutical services. It develops inhaled medicines for viral and fungal infections of the respiratory tract. The company was founded by William Garth Rapeport, John Murray, Kazuhiro Ito, and Peter Strong on March 23, 2007 and is headquartered in London, the United Kingdom. | Health Technology |
| Glaxo Wellcome Plc | Health Technology |
